LSP-249

• Description :

  LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell[1].

• UNSPSC :

  12352005

• Target :

  Kallikrein

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/lsp-249.html

• Concentration :

  10mM

• Purity :

  99.05

• Solubility :

  DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(C1=CC(CC2=CC=C3N=CC(Cl)=CC3=C2)=NC=C1)NCC4=C(C)C=C(N)N=C4C

• Molecular Formula :

  C24H22ClN5O

• Molecular Weight :

  431.92

• References & Citations :

  [1]Andrew Mcdonald, et al. Therapeutic inhibitory compounds. Patent. WO2016011209A1.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1801253-04-2]